{"protocolSection": {"identificationModule": {"nctId": "NCT00454818", "orgStudyIdInfo": {"id": "CELL-001"}, "secondaryIdInfos": [{"id": "CUPID Trial", "type": "REGISTRY", "domain": "NCT00454818"}], "organization": {"fullName": "Celladon Corporation", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure", "officialTitle": "A Phase 1/2 Trial of Intracoronary Administration of MYDICAR\u00ae (AAV1/SERCA2a) in Subjects With Heart Failure in Two Stages (Open-Label, Sequential Dose-Escalation Cohorts and Randomized, Double-Blind, Placebo-Controlled, Parallel Cohorts)", "acronym": "CUPID"}, "statusModule": {"statusVerifiedDate": "2014-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-03"}, "primaryCompletionDateStruct": {"date": "2010-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-03-30", "studyFirstSubmitQcDate": "2007-03-30", "studyFirstPostDateStruct": {"date": "2007-04-02", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-06-25", "resultsFirstSubmitQcDate": "2014-08-19", "resultsFirstPostDateStruct": {"date": "2014-08-20", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-08-19", "lastUpdatePostDateStruct": {"date": "2014-08-20", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Celladon Corporation", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The study is divided into 2 parts. In the first part, the safety of the gene transfer agent MYDICAR\u00ae will be evaluated. In the second part, the ability of MYDICAR\u00ae to improve heart function will be studied.", "detailedDescription": "The American Heart Association (AHA) 2006 update on heart disease reported that 5 million Americans are believed to have symptomatic heart failure (HF), and 550,000 patients are newly diagnosed each year. The estimated direct and indirect cost of HF in the United States (U.S.) for 2006 will be \\~$29.6 billion. Heart failure is a disabling chronic disease and the most frequent discharge diagnosis for hospitalization among older adults. Despite the significant resources expended on the treatment of this disease, outcomes remain poor. The five-year survival for individuals diagnosed with heart failure is less than 50%, and in end-stage heart failure, the one-year survival may be as low as 25% regardless of medical therapy.\n\nRecent studies suggest that the failing heart is not refractory to treatment, as was previously believed. For example, the observation that a small percentage of subjects with left ventricular assist devices (LVADs) can be permanently weaned from their device strongly suggests that damaged hearts are capable of recovering lost function.\n\nClinical studies of MYDICAR\u00ae have not yet been conducted in humans. Celladon Corporation (Celladon) proposes to investigate gene transfer as a method to restore SERCA2a function in heart failure (HF) patients using a recombinant adeno-associated viral vector (AAV), which consists of an AAV serotype 1 capsid and contains the human SERCA2a complementary DNA (cDNA) flanked by Inverted Terminal Repeats (ITR) derived from AAV serotype 2 (AAV1/SERCA2a). MYDICAR\u00ae refers to AAV1/SERCA2a drug product intended for administration by percutaneous delivery."}, "conditionsModule": {"conditions": ["Heart Failure, Congestive", "Dilated Cardiomyopathy"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 51, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "MYDICAR Very Low Dose", "type": "EXPERIMENTAL", "description": "Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1.4x10e11 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) only.", "interventionNames": ["Genetic: MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)"]}, {"label": "MYDICAR Low Dose", "type": "EXPERIMENTAL", "description": "Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6x10e11 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) and MYDICAR Phase 2 (Placebo-controlled, Randomized Study)", "interventionNames": ["Genetic: MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)", "Genetic: MYDICAR Phase 2 (Placebo-controlled, Randomized Study)"]}, {"label": "MYDICAR Mid Dose", "type": "EXPERIMENTAL", "description": "Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3x10e12 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) and MYDICAR Phase 2 (Placebo-controlled, Randomized Study).", "interventionNames": ["Genetic: MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)", "Genetic: MYDICAR Phase 2 (Placebo-controlled, Randomized Study)"]}, {"label": "MYDICAR High Dose", "type": "EXPERIMENTAL", "description": "Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1x10e13 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) and MYDICAR Phase 2 (Placebo-controlled, Randomized Study).", "interventionNames": ["Genetic: MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)", "Genetic: MYDICAR Phase 2 (Placebo-controlled, Randomized Study)"]}, {"label": "Placebo infusion", "type": "PLACEBO_COMPARATOR", "description": "A single dose of placebo (Sodium Chloride Injection, USP) administered by antegrade epicardial coronary artery infusion.", "interventionNames": ["Procedure: Placebo Infusion"]}], "interventions": [{"type": "GENETIC", "name": "MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)", "description": "MYDICAR administered by antegrade epicardial coronary artery infusion", "armGroupLabels": ["MYDICAR High Dose", "MYDICAR Low Dose", "MYDICAR Mid Dose", "MYDICAR Very Low Dose"], "otherNames": ["AAV1/SERCA2a"]}, {"type": "PROCEDURE", "name": "Placebo Infusion", "description": "Saline; epicardial coronary artery infusion", "armGroupLabels": ["Placebo infusion"]}, {"type": "GENETIC", "name": "MYDICAR Phase 2 (Placebo-controlled, Randomized Study)", "description": "MYDICAR administered by antegrade epicardial coronary artery infusion", "armGroupLabels": ["MYDICAR High Dose", "MYDICAR Low Dose", "MYDICAR Mid Dose"], "otherNames": ["AAV1/SERCA2a"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Phase 2: Incidence of Treatment-emergent Adverse Events (TEAE) at 12 Months", "description": "Includes all adverse events that occurred from the time of first infusion of the investigational product or placebo to the 12-month visit. The category of \"TEAEs related to the investigational product (IP)\" includes TEAEs considered by the investigator to be possibly, probably, or definitely related to the IP.", "timeFrame": "12 months"}, {"measure": "Phase 2: Length of Cardiovascular-related Hospitalizations at 6 Months", "description": "Mean number of days in the hospital for cardiovascular-related complications. All hospitalizations were evaluated and classified by the blinded Clinical Endpoints Committee.", "timeFrame": "6 months"}, {"measure": "Phase 2: Change in Symptomatic Efficacy Domains From Baseline to Month 6: New York Heart Association (NYHA) Class and Minnesota Living With Heart Failure Questionnaire (MLWHFQ) Score", "description": "NYHA classification is a symptomatic assessment in which the investigator evaluates subjects on a scale ranging from Class I (subjects with no limitation of activities, no symptoms from ordinary activities) to Class IV (subjects who should be at complete rest, confined to bed or chair; any physical activity brings on discomfort and symptoms occur at rest).\n\nThe MLWHFQ is a patient-reported quality of life (QoL) measure in which patients assess the impact of their heart condition on activities in the past month using a Likert scale ranging from 0 (no effect) to 5 (very much effect). Higher scores thus indicate a lower QoL. The maximum (worst) score is 105 and the minimum (best) score is 0.\n\nFor both measures, changes from baseline with positive values indicate a worsening in symptoms and changes from baseline with negative values indicate an improvement in symptoms.", "timeFrame": "Baseline to 6 months"}, {"measure": "Phase 2: Change in 6-minute Walk Test (6MWT) From Baseline to Month 6", "description": "The 6MWT measures the distance walked in meters during a 6-minute test. Higher values indicate a better functional status. Changes from baseline with negative values indicate a worsening in function and changes from baseline with positive values indicate an improvement in function.", "timeFrame": "Baseline to 6 months"}, {"measure": "Phase 2: Change in Peak Maximum Oxygen Consumption (VO2) From Baseline to Month 6", "description": "Peak VO2 is a measure of maximal oxygen consumption during cardiopulmonary exercise testing; this study used the modified Naughton treadmill protocol. Higher values indicate a better functional status. Changes from baseline with negative values indicate a worsening in function and changes from baseline with positive values indicate an improvement in function.", "timeFrame": "Baseline to 6 months"}, {"measure": "Phase 2: Change in Absolute Levels of N-terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) From Baseline to Month 6", "description": "NT-proBNP is a biomarker for heart failure. Increased levels of this biomarker are associated with increased mortality and cardiovascular hospitalization in patients with heart failure.", "timeFrame": "Baseline to 6 months"}, {"measure": "Phase 2: Change in Percentage of Blood Ejected From the Left Ventricle (LV) (i.e., Left Ventricular Ejection Fraction [LVEF]) From Baseline to Month 6", "description": "Contrast echocardiography was used to determine LVEF. Increases in LVEF are associated with reduced mortality. Changes from baseline with positive values indicate an improvement in heart function and changes from baseline with negative values indicate a worsening of heart function.", "timeFrame": "Baseline to 6 months"}, {"measure": "Phase 2: Change in Absolute Left Ventricular End Systolic Volume (LVESV) Frm Baseline to Month 6", "description": "Contrast echocardiography was used to determine LVESV. Decreases in LVESV are associated with reduced mortality. Changes from baseline with positive values indicate a worsening in heart function and changes from baseline with negative values indicate an improvement in symptoms.", "timeFrame": "Baseline to 6 months"}], "otherOutcomes": [{"measure": "Phase 2: Length of Cardiovascular-related Hospitalizations at 12 Months", "description": "Mean number of days in the hospital for cardiovascular-related complications. All hospitalizations were evaluated and classified by the blinded Clinical Endpoints Committee.", "timeFrame": "12 months"}, {"measure": "Phase 2: Change in Symptomatic Efficacy Domains From Baseline to Month 12: New York Heart Association (NYHA) Class and Minnesota Living With Heart Failure Questionnaire (MLWHFQ) Score", "description": "NYHA classification is a symptomatic assessment in which the investigator evaluates subjects on a scale ranging from Class I (subjects with no limitation of activities, no symptoms from ordinary activities) to Class IV (subjects who should be at complete rest, confined to bed or chair; any physical activity brings on discomfort and symptoms occur at rest).\n\nThe MLWHFQ is a patient-reported quality of life (QoL) measure in which patients assess the impact of their heart condition on activities in the past month using a Likert scale ranging from 0 (no effect) to 5 (very much effect). Higher scores thus indicate a lower QoL. The maximum (worst) score is 105 and the minimum (best) score is 0.\n\nFor both measures, changes from baseline with positive values indicate a worsening in symptoms and changes from baseline with negative values indicate an improvement in symptoms.", "timeFrame": "Baseline to 12 months"}, {"measure": "Phase 2: Change in 6-minute Walk Test (6MWT) From Baseline to Month 12", "description": "The 6MWT measures the distance walked in meters during a 6-minute test. Higher values indicate a better functional status. Changes from baseline with negative values indicate a worsening in function and changes from baseline with positive values indicate an improvement in function.", "timeFrame": "Baseline to 12 months"}, {"measure": "Phase 2: Change in Peak Maximum Oxygen Consumption (VO2) From Baseline to Month 12", "description": "Peak VO2 is a measure of maximal oxygen consumption during cardiopulmonary exercise testing; this study used the modified Naughton treadmill protocol. Higher values indicate a better functional status. Changes from baseline with negative values indicate a worsening in function and changes from baseline with positive values indicate an improvement in function.", "timeFrame": "Baseline to 12 months"}, {"measure": "Phase 2: Change in Absolute Levels of N-terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) From Baseline to Month 12", "description": "NT-proBNP is a biomarker for heart failure. Increased levels of this biomarker are associated with increased mortality and cardiovascular hospitalization in patients with heart failure.", "timeFrame": "Baseline to 12 months"}, {"measure": "Phase 2: Change in Percentage of Blood Ejected From the Left Ventricle (LV) (i.e., Left Ventricular Ejection Fraction [LVEF]) From Baseline to Month 12", "description": "Contrast echocardiography was used to determine LVEF. Increases in LVEF are associated with reduced mortality. Changes from baseline with positive values indicate an improvement in heart function and changes from baseline with negative values indicate a worsening of heart function.", "timeFrame": "Baseline to 12 months"}, {"measure": "Phase 2: Change in Absolute Left Ventricular End Systolic Volume (LVESV) From Baseline to Month 12", "description": "Contrast echocardiography was used to determine LVESV. Decreases in LVESV are associated with reduced mortality. Changes from baseline with positive values indicate a worsening in heart function and changes from baseline with negative values indicate an improvement in symptoms.", "timeFrame": "Baseline to 12 months"}, {"measure": "Phase 1 and Phase 2: All Subject Deaths Through 36 Months", "description": "All subject deaths that occurred during the 12-month study or the 24-month follow-up in subjects enrolled in either the Phase 1 or Phase 2 trial. Events occurring after early termination from the trial are listed as occurring during long-term follow-up, but may have been within 12 months. Specifically, two cardiovascular (CV) deaths in placebo subjects occurred following early study termination, but within 12 months of study initiation. These deaths are therefore included under \"Deaths within 12 months\" but also listed as \"Cardiovascular deaths in long-term follow-up.\" Accordingly, the number of \"Cardiovascular deaths in long-term follow-up\" for the placebo group is greater than the number of \"Deaths after 12 months,\" as 2 of the deaths occurred within 12 months but after early termination.", "timeFrame": "36 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Chronic ischemic or non-ischemic cardiomyopathy. Subjects with ischemic cardiomyopathy must have at least one major coronary vessel with Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow.\n* Left ventricular ejection fraction (LVEF) \u226435%\n* Diagnosis of New York Heart Association (NYHA) Class III/IV heart failure for a minimum of 3 months prior to screening\n* Maximal oxygen consumption (VO2 max) \u226420 mL/kg/min within 90 days prior to enrollment\n* An implantable cardioverter defibrillator (ICD) implanted a minimum of 30 days prior to enrollment\n* Treatment with appropriate heart failure therapy as tolerated\n* All women of childbearing potential must have a negative urine pregnancy test prior to administration of investigational product and agree to use adequate contraception. Men capable of fathering a child must agree to use barrier contraception or limit activity to post-menopausal, surgically sterilized, or a contraception-practicing partner, for 3 months after administration of investigational product.\n* Ability to sign Informed Consent Form (ICF) and Release of Medical Information Form\n\nExclusion Criteria:\n\n* Any intravenous therapy with positive inotropes, vasodilators, or diuretics within 30 days prior to enrollment\n* Restrictive cardiomyopathy, obstructive cardiomyopathy, pericardial disease, amyloidosis, infiltrative cardiomyopathy, uncorrected thyroid disease, or dyskinetic LV aneurysm\n* Cardiac surgery, percutaneous coronary intervention, or valvuloplasty within 30 days prior to enrollment\n* Clinically significant myocardial infarction (e.g., ST elevation MI \\[STEMI\\] or large non-STEMI) within 6 months prior to enrollment\n* Prior heart transplantation, left ventricular reduction surgery (LVRS), cardiomyoplasty, passive restraint device (e.g., CorCap\u2122 Cardiac Support Device), surgically implanted LVAD or cardiac shunt\n* Likely to receive cardiac resynchronization therapy, cardiomyoplasty, LVRS, heart transplant, conventional revascularization procedure, or valvular repair within 6 months following enrollment\n* Patients with prior coronary artery bypass graft(s) (CABG) will reviewed on a case-by-case basis\n* No evidence of functional or viable myocardium\n* Exercise capacity primarily limited by obesity, peripheral vascular disease, intrinsic pulmonary disease or orthopedic problems and not by underlying heart failure\n* Known hypersensitivity to octafluoropropane (component of the intravenous echocardiography contrast agent, DEFINITY\u00ae) or other contrast dyes used for angiography; history of, or likely need for, high dose steroid pretreatment prior to contrast angiography\n* A left ventricle that is difficult to image or high quality echocardiography is not obtainable at screening\n* Significant left main or ostial right coronary lumenal stenosis in the opinion of the investigator\n* Expected survival \\<1 year in the investigator's medical opinion\n* Suspected or active viral, bacterial, fungal, or parasitic infection within 48 hours prior to enrollment\n* Liver function tests (alanine aminotransferase \\[ALT\\], aspartate aminotransferase \\[AST\\], alkaline phosphatase) \\>2x Upper Limit of Normal (ULN) within 30 days prior to enrollment or known intrinsic liver disease (e.g., cirrhosis, chronic hepatitis B or hepatitis C virus infection)\n* Current or likely need for hemodialysis within 12 months following enrollment\n* Bleeding diathesis or thrombocytopenia defined as platelet count \\<50,000 platelets/\u03bcL\n* Anemia defined as hemoglobin \\<10 g/dL\n* Known AIDS or HIV-positive status, or a previous diagnosis of immunodeficiency with an absolute neutrophil count \\<1000 cells/mm3\n* Previous participation in a study of gene transfer\n* Presence of neutralizing anti-AAV1 antibodies at titer \u22651:2 within 3 months of screening\n* Receiving investigational intervention or participating in another clinical study within 30 days or within 5 half-lives of the investigational drug administration prior to enrollment\n* Pregnancy or lactation\n* Recent history of psychiatric disease (including drug or alcohol abuse) that is likely to impair subject's ability to comply with protocol-mandated procedures, in the opinion of the investigator\n* Other concurrent medical condition(s) that, while not explicitly excluded by the protocol, could jeopardize the safety of the patient or objectives of the study", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Brian Jaski, MD", "affiliation": "San Diego Cardiac Center", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Donna Mancini, MD", "affiliation": "Columbia University Hospital", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Randall Starling, MD", "affiliation": "The Cleveland Clinic", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Mariell Jessup, MD", "affiliation": "University of Pennsylvania", "role": "STUDY_CHAIR"}, {"name": "Thomas Cappola, MD, ScM", "affiliation": "University of Pennsylvania", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Daniel Pauly, MD", "affiliation": "Shands Hospital, University of Florida at Gainesville", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Barry London, MD", "affiliation": "University of Pittsburgh Medical Center", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Barry Greenberg, MD", "affiliation": "University of California at San Diego Medical Center", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "A. G. Kfoury, MD", "affiliation": "Intermountain Medical Center", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Stephen Archer, MD", "affiliation": "University of Chicago", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Andrew Kao, MD", "affiliation": "Mid America Heart Institute, Saint Luke's Hospital", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Paul J. Hauptman, MD", "affiliation": "St. Louis University Hospital", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Jill Kalman, MD", "affiliation": "Icahn School of Medicine at Mount Sinai", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Douglas W. Losordo, MD", "affiliation": "Northwestern University", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Eric J. Eichhorn, MD, FACC", "affiliation": "Cardiopulmonary Research Science and Technology Institutte, Medical City Dallas Hospital", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Stephanie H. Dunlap, DO", "affiliation": "University of Cincinnati", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Vinay Thohan, MD", "affiliation": "Wake Forest University", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Maryl R. Johnson, MD", "affiliation": "University of Wisconsin, Madison", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Mark Dunlap, MD", "affiliation": "MetroHealth Medical Center", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Joaquin E. Cigarroa, MD", "affiliation": "Oregon Health and Science University", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Dinesh K. Gupta, MD", "affiliation": "Tennessee Center for Clinical Trials, Harton Regional Medical Center", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Marc Klapholz, MD", "affiliation": "University of Medicine and Dentistry of New Jersey", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Guillermo Torre, MD", "affiliation": "The Methodist Hospital Research Institute", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of California at San Diego Medical Center", "city": "San Diego", "state": "California", "zip": "92103", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "San Diego Cardiac Center", "city": "San Diego", "state": "California", "zip": "92123", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Shands Hospital at University of Florida", "city": "Gainesville", "state": "Florida", "zip": "32608", "country": "United States", "geoPoint": {"lat": 29.65163, "lon": -82.32483}}, {"facility": "Northwestern University", "city": "Chicago", "state": "Illinois", "zip": "60611", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "University of Chicago Medical Center", "city": "Chicago", "state": "Illinois", "zip": "60637", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Mid America Heart Institute, Saint Luke's Hospital", "city": "Kansas City", "state": "Missouri", "zip": "64111", "country": "United States", "geoPoint": {"lat": 39.09973, "lon": -94.57857}}, {"facility": "St. Louis University Hospital", "city": "St. Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "University of Medicine and Dentistry of New Jersey", "city": "Newark", "state": "New Jersey", "zip": "07101", "country": "United States", "geoPoint": {"lat": 40.73566, "lon": -74.17237}}, {"facility": "Mount Sinai Medical Center", "city": "New York", "state": "New York", "zip": "10029", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Columbia University Hospital", "city": "New York", "state": "New York", "zip": "10032", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Wake Forest University", "city": "Winston-Salem", "state": "North Carolina", "zip": "27157", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "University of Cincinnati", "city": "Cincinnati", "state": "Ohio", "zip": "45267", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "MetroHealth Medical Center", "city": "Cleveland", "state": "Ohio", "zip": "44109", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "Cleveland Clinic Foundation", "city": "Cleveland", "state": "Ohio", "zip": "44195", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "Oregon Health and Science University", "city": "Portland", "state": "Oregon", "zip": "97239", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "Hospital of the University of Pennsylvania", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19104", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "University of Pittsburgh Medical Center, Presbyterian-Shadyside Hospital", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15213", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Tennessee Center for Clinical Trials & Harton Regional Medical Center", "city": "Tullahoma", "state": "Tennessee", "zip": "37388", "country": "United States", "geoPoint": {"lat": 35.36202, "lon": -86.20943}}, {"facility": "Cardiopulmonary Research Science and Technology Institute, Medical City Dallas Hospital", "city": "Dallas", "state": "Texas", "zip": "75230", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Methodist Hospital", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Intermountain Medical Center", "city": "Murray", "state": "Utah", "zip": "84157", "country": "United States", "geoPoint": {"lat": 40.66689, "lon": -111.88799}}, {"facility": "University of Wisconsin", "city": "Madison", "state": "Wisconsin", "zip": "53792", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}]}, "referencesModule": {"references": [{"pmid": "21340529", "type": "BACKGROUND", "citation": "Horowitz JD, Rosenson RS, McMurray JJ, Marx N, Remme WJ. Clinical Trials Update AHA Congress 2010. Cardiovasc Drugs Ther. 2011 Feb;25(1):69-76. doi: 10.1007/s10557-011-6285-9."}, {"pmid": "18514926", "type": "BACKGROUND", "citation": "Hajjar RJ, Zsebo K, Deckelbaum L, Thompson C, Rudy J, Yaroshinsky A, Ly H, Kawase Y, Wagner K, Borow K, Jaski B, London B, Greenberg B, Pauly DF, Patten R, Starling R, Mancini D, Jessup M. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail. 2008 Jun;14(5):355-67. doi: 10.1016/j.cardfail.2008.02.005. Epub 2008 May 27."}, {"pmid": "19327618", "type": "RESULT", "citation": "Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Greenberg B, Borow K, Dittrich H, Zsebo KM, Hajjar RJ; Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID) Trial Investigators. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail. 2009 Apr;15(3):171-81. doi: 10.1016/j.cardfail.2009.01.013."}, {"pmid": "21709064", "type": "RESULT", "citation": "Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ; Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation. 2011 Jul 19;124(3):304-13. doi: 10.1161/CIRCULATIONAHA.111.022889. Epub 2011 Jun 27."}, {"pmid": "24065463", "type": "RESULT", "citation": "Zsebo K, Yaroshinsky A, Rudy JJ, Wagner K, Greenberg B, Jessup M, Hajjar RJ. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res. 2014 Jan 3;114(1):101-8. doi: 10.1161/CIRCRESAHA.113.302421. Epub 2013 Sep 24."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "MYDICAR\u00ae Very Low Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1.4E11 DNAase resistant particles (DRP) administered by antegrade epicardial coronary artery infusion.\n\nThis arm was included only in the Phase I open-label dose-escalation period."}, {"id": "FG001", "title": "MYDICAR\u00ae Low Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6E11 DNAase resistant particles (DRP) administered by antegrade epicardial coronary artery infusion."}, {"id": "FG002", "title": "MYDICAR\u00ae Mid Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3E12 DNAase resistant particles (DRP) administered by antegrade epicardial coronary artery infusion."}, {"id": "FG003", "title": "MYDICAR\u00ae High Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1E13 DNAase resistant particles (DRP) administered by antegrade epicardial coronary artery infusion."}, {"id": "FG004", "title": "Placebo", "description": "Single dose of placebo administered by antegrade epicardial coronary artery infusion.\n\nThe placebo arm was included only in the Phase 2 randomized double-blind period."}], "periods": [{"title": "Phase I: Open-label Dose-escalation", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Received heart transplant", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Received left ventricular assist device", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}]}]}, {"title": "Phase 2: Randomized Double-blind", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "9"}, {"groupId": "FG004", "numSubjects": "14"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "8"}, {"groupId": "FG004", "numSubjects": "10"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Received milrinone or dobutamine", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}]}, {"type": "Received a heart transplant", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}]}, {"type": "Received left ventricular assist device", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Baseline data are provided for subjects enrolled in the Phase 1 or Phase 2 trials.", "groups": [{"id": "BG000", "title": "Phase 1: MYDICAR\u00ae Very Low Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1.4E11 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "BG001", "title": "Phase 1: MYDICAR\u00ae Low Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6E11 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "BG002", "title": "Phase 1: MYDICAR\u00ae Mid Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3E12 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "BG003", "title": "Phase 1: MYDICAR\u00ae High Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1E13 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "BG004", "title": "Phase 2: MYDICAR\u00ae Low Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6E11 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "BG005", "title": "Phase 2: MYDICAR\u00ae Mid Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3E12 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "BG006", "title": "Phase 2: MYDICAR\u00ae High Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1E13 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "BG007", "title": "Phase 2: Placebo", "description": "Single dose of placebo administered by antegrade epicardial coronary artery infusion."}, {"id": "BG008", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "3"}, {"groupId": "BG004", "value": "8"}, {"groupId": "BG005", "value": "8"}, {"groupId": "BG006", "value": "9"}, {"groupId": "BG007", "value": "14"}, {"groupId": "BG008", "value": "51"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "53.7", "spread": "7.02"}, {"groupId": "BG001", "value": "55.7", "spread": "4.51"}, {"groupId": "BG002", "value": "48.0", "spread": "8.54"}, {"groupId": "BG003", "value": "58.77", "spread": "19.01"}, {"groupId": "BG004", "value": "60.3", "spread": "10.27"}, {"groupId": "BG005", "value": "63.9", "spread": "8.85"}, {"groupId": "BG006", "value": "56.6", "spread": "13.96"}, {"groupId": "BG007", "value": "61.0", "spread": "11.94"}, {"groupId": "BG008", "value": "60.5", "spread": "11.39"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "1"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "3"}, {"groupId": "BG007", "value": "1"}, {"groupId": "BG008", "value": "8"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "7"}, {"groupId": "BG005", "value": "8"}, {"groupId": "BG006", "value": "6"}, {"groupId": "BG007", "value": "13"}, {"groupId": "BG008", "value": "43"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "3"}, {"groupId": "BG007", "value": "1"}, {"groupId": "BG008", "value": "6"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "3"}, {"groupId": "BG004", "value": "8"}, {"groupId": "BG005", "value": "8"}, {"groupId": "BG006", "value": "6"}, {"groupId": "BG007", "value": "13"}, {"groupId": "BG008", "value": "45"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Phase 2: Incidence of Treatment-emergent Adverse Events (TEAE) at 12 Months", "description": "Includes all adverse events that occurred from the time of first infusion of the investigational product or placebo to the 12-month visit. The category of \"TEAEs related to the investigational product (IP)\" includes TEAEs considered by the investigator to be possibly, probably, or definitely related to the IP.", "populationDescription": "This analysis was performed on the intention to treat population of the Phase 2 period, which included all patients randomized to treatment in the Phase 2 trial.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "12 months", "groups": [{"id": "OG000", "title": "MYDICAR\u00ae Low Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6E11 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG001", "title": "MYDICAR\u00ae Mid Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3E12 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG002", "title": "MYDICAR\u00ae High Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1E13 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG003", "title": "Placebo", "description": "Single dose of placebo administered by antegrade epicardial coronary artery infusion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"title": "Any TEAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "100"}, {"groupId": "OG001", "value": "100"}, {"groupId": "OG002", "value": "88.9"}, {"groupId": "OG003", "value": "92.9"}]}]}, {"title": "TEAEs related to the investigational product (IP)", "categories": [{"measurements": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "12.5"}, {"groupId": "OG002", "value": "11.1"}, {"groupId": "OG003", "value": "57.1"}]}]}, {"title": "TEAEs related to administration of the IP", "categories": [{"measurements": [{"groupId": "OG000", "value": "12.5"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "11.1"}, {"groupId": "OG003", "value": "57.1"}]}]}, {"title": "Serious TEAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "62.5"}, {"groupId": "OG001", "value": "50"}, {"groupId": "OG002", "value": "33.3"}, {"groupId": "OG003", "value": "64.3"}]}]}, {"title": "Serious TEAEs related to the IP", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "21.4"}]}]}, {"title": "Serious TEAEs related to IP administration", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "28.6"}]}]}]}, {"type": "PRIMARY", "title": "Phase 2: Length of Cardiovascular-related Hospitalizations at 6 Months", "description": "Mean number of days in the hospital for cardiovascular-related complications. All hospitalizations were evaluated and classified by the blinded Clinical Endpoints Committee.", "populationDescription": "This analysis was performed on the intention to treat population of the Phase 2 period, which included all patients randomized to treatment in the Phase 2 trial.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "days", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "MYDICAR\u00ae Low Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6E11 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG001", "title": "MYDICAR\u00ae Mid Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3E12 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG002", "title": "MYDICAR\u00ae High Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1E13 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG003", "title": "Placebo", "description": "Single dose of placebo administered by antegrade epicardial coronary artery infusion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.3", "spread": "0.46"}, {"groupId": "OG001", "value": "1.3", "spread": "2.55"}, {"groupId": "OG002", "value": "0.2", "spread": "0.67"}, {"groupId": "OG003", "value": "2.1", "spread": "2.92"}]}]}], "analyses": [{"groupIds": ["OG002", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.078", "pValueComment": "The a priori threshold for statistical significance was P \\< 0.2. There were no adjustments for multiple comparisons.", "statisticalMethod": "t-test, 2 sided"}, {"groupIds": ["OG001", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.515", "pValueComment": "The a priori threshold for statistical significance was P \\< 0.2. There were no adjustments for multiple comparisons.", "statisticalMethod": "t-test, 2 sided"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.098", "pValueComment": "The a priori threshold for statistical significance was P \\< 0.2. There were no adjustments for multiple comparisons.", "statisticalMethod": "t-test, 2 sided"}]}, {"type": "PRIMARY", "title": "Phase 2: Change in Symptomatic Efficacy Domains From Baseline to Month 6: New York Heart Association (NYHA) Class and Minnesota Living With Heart Failure Questionnaire (MLWHFQ) Score", "description": "NYHA classification is a symptomatic assessment in which the investigator evaluates subjects on a scale ranging from Class I (subjects with no limitation of activities, no symptoms from ordinary activities) to Class IV (subjects who should be at complete rest, confined to bed or chair; any physical activity brings on discomfort and symptoms occur at rest).\n\nThe MLWHFQ is a patient-reported quality of life (QoL) measure in which patients assess the impact of their heart condition on activities in the past month using a Likert scale ranging from 0 (no effect) to 5 (very much effect). Higher scores thus indicate a lower QoL. The maximum (worst) score is 105 and the minimum (best) score is 0.\n\nFor both measures, changes from baseline with positive values indicate a worsening in symptoms and changes from baseline with negative values indicate an improvement in symptoms.", "populationDescription": "This analysis was performed on the intention to treat population of the Phase 2 period, which included all patients randomized to treatment in the Phase 2 trial.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline to 6 months", "groups": [{"id": "OG000", "title": "MYDICAR\u00ae Low Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6E11 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG001", "title": "MYDICAR\u00ae Mid Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3E12 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG002", "title": "MYDICAR\u00ae High Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1E13 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG003", "title": "Placebo", "description": "Single dose of placebo administered by antegrade epicardial coronary artery infusion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"title": "Change in NHYA class", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.8", "spread": "0.71"}, {"groupId": "OG001", "value": "-0.8", "spread": "0.89"}, {"groupId": "OG002", "value": "-0.6", "spread": "0.73"}, {"groupId": "OG003", "value": "-0.2", "spread": "0.70"}]}]}, {"title": "Change in MLWHFQ score", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.6", "spread": "20.99"}, {"groupId": "OG001", "value": "7.9", "spread": "27.28"}, {"groupId": "OG002", "value": "-10.3", "spread": "12.21"}, {"groupId": "OG003", "value": "3.4", "spread": "36.00"}]}]}]}, {"type": "PRIMARY", "title": "Phase 2: Change in 6-minute Walk Test (6MWT) From Baseline to Month 6", "description": "The 6MWT measures the distance walked in meters during a 6-minute test. Higher values indicate a better functional status. Changes from baseline with negative values indicate a worsening in function and changes from baseline with positive values indicate an improvement in function.", "populationDescription": "This analysis was performed on the intention to treat population of the Phase 2 period, which included all patients randomized to treatment in the Phase 2 trial.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "meters", "timeFrame": "Baseline to 6 months", "groups": [{"id": "OG000", "title": "MYDICAR\u00ae Low Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6E11 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG001", "title": "MYDICAR\u00ae Mid Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3E12 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG002", "title": "MYDICAR\u00ae High Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1E13 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG003", "title": "Placebo", "description": "Single dose of placebo administered by antegrade epicardial coronary artery infusion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13.0", "spread": "61.40"}, {"groupId": "OG001", "value": "-59.5", "spread": "213.64"}, {"groupId": "OG002", "value": "1.0", "spread": "99.69"}, {"groupId": "OG003", "value": "-86.6", "spread": "164.30"}]}]}]}, {"type": "PRIMARY", "title": "Phase 2: Change in Peak Maximum Oxygen Consumption (VO2) From Baseline to Month 6", "description": "Peak VO2 is a measure of maximal oxygen consumption during cardiopulmonary exercise testing; this study used the modified Naughton treadmill protocol. Higher values indicate a better functional status. Changes from baseline with negative values indicate a worsening in function and changes from baseline with positive values indicate an improvement in function.", "populationDescription": "This analysis was performed on the intention to treat population of the Phase 2 period, which included all patients randomized to treatment in the Phase 2 trial.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL/kg per minute", "timeFrame": "Baseline to 6 months", "groups": [{"id": "OG000", "title": "MYDICAR\u00ae Low Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6E11 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG001", "title": "MYDICAR\u00ae Mid Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3E12 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG002", "title": "MYDICAR\u00ae High Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1E13 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG003", "title": "Placebo", "description": "Single dose of placebo administered by antegrade epicardial coronary artery infusion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.73", "spread": "4.88"}, {"groupId": "OG001", "value": "-1.07", "spread": "5.076"}, {"groupId": "OG002", "value": "-0.43", "spread": "0,802"}, {"groupId": "OG003", "value": "-2.10", "spread": "4.462"}]}]}]}, {"type": "PRIMARY", "title": "Phase 2: Change in Absolute Levels of N-terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) From Baseline to Month 6", "description": "NT-proBNP is a biomarker for heart failure. Increased levels of this biomarker are associated with increased mortality and cardiovascular hospitalization in patients with heart failure.", "populationDescription": "This analysis was performed on the intention to treat population of the Phase 2 period, which included all patients randomized to treatment in the Phase 2 trial. NT-proBNP data were not available for 1 patient in the MYDICAR high dose group.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL", "timeFrame": "Baseline to 6 months", "groups": [{"id": "OG000", "title": "MYDICAR\u00ae Low Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6E11 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG001", "title": "MYDICAR\u00ae Mid Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3E12 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG002", "title": "MYDICAR\u00ae High Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1E13 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG003", "title": "Placebo", "description": "Single dose of placebo administered by antegrade epicardial coronary artery infusion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "694.1", "spread": "1444.94"}, {"groupId": "OG001", "value": "2073.1", "spread": "4224.22"}, {"groupId": "OG002", "value": "-13.5", "spread": "928.48"}, {"groupId": "OG003", "value": "5540.0", "spread": "11,873.46"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Phase 2: Length of Cardiovascular-related Hospitalizations at 12 Months", "description": "Mean number of days in the hospital for cardiovascular-related complications. All hospitalizations were evaluated and classified by the blinded Clinical Endpoints Committee.", "populationDescription": "This analysis was performed on the intention to treat population of the Phase 2 period, which included all patients randomized to treatment in the Phase 2 trial.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "days", "timeFrame": "12 months", "groups": [{"id": "OG000", "title": "MYDICAR\u00ae Low Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6E11 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG001", "title": "MYDICAR\u00ae Mid Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3E12 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG002", "title": "MYDICAR\u00ae High Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1E13 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG003", "title": "Placebo", "description": "Single dose of placebo administered by antegrade epicardial coronary artery infusion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10.1", "spread": "12.71"}, {"groupId": "OG001", "value": "7.4", "spread": "11.80"}, {"groupId": "OG002", "value": "0.4", "spread": "1.33"}, {"groupId": "OG003", "value": "4.5", "spread": "5.80"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Phase 2: Change in Symptomatic Efficacy Domains From Baseline to Month 12: New York Heart Association (NYHA) Class and Minnesota Living With Heart Failure Questionnaire (MLWHFQ) Score", "description": "NYHA classification is a symptomatic assessment in which the investigator evaluates subjects on a scale ranging from Class I (subjects with no limitation of activities, no symptoms from ordinary activities) to Class IV (subjects who should be at complete rest, confined to bed or chair; any physical activity brings on discomfort and symptoms occur at rest).\n\nThe MLWHFQ is a patient-reported quality of life (QoL) measure in which patients assess the impact of their heart condition on activities in the past month using a Likert scale ranging from 0 (no effect) to 5 (very much effect). Higher scores thus indicate a lower QoL. The maximum (worst) score is 105 and the minimum (best) score is 0.\n\nFor both measures, changes from baseline with positive values indicate a worsening in symptoms and changes from baseline with negative values indicate an improvement in symptoms.", "populationDescription": "This analysis was performed on the intention to treat population, which included all patients randomized to treatment.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline to 12 months", "groups": [{"id": "OG000", "title": "MYDICAR\u00ae Low Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6E11 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG001", "title": "MYDICAR\u00ae Mid Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3E12 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG002", "title": "MYDICAR\u00ae High Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1E13 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG003", "title": "Placebo", "description": "Single dose of placebo administered by antegrade epicardial coronary artery infusion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"title": "Change in NHYA class", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "spread": "0.99"}, {"groupId": "OG001", "value": "0.1", "spread": "0.83"}, {"groupId": "OG002", "value": "-0.3", "spread": "0.71"}, {"groupId": "OG003", "value": "0.1", "spread": "0.73"}]}]}, {"title": "Change in MLWHFQ score", "categories": [{"measurements": [{"groupId": "OG000", "value": "24.4", "spread": "37.3"}, {"groupId": "OG001", "value": "22.5", "spread": "32.56"}, {"groupId": "OG002", "value": "0.1", "spread": "23.80"}, {"groupId": "OG003", "value": "14.7", "spread": "34.89"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Phase 2: Change in 6-minute Walk Test (6MWT) From Baseline to Month 12", "description": "The 6MWT measures the distance walked in meters during a 6-minute test. Higher values indicate a better functional status. Changes from baseline with negative values indicate a worsening in function and changes from baseline with positive values indicate an improvement in function.", "populationDescription": "This analysis was performed on the intention to treat population of the Phase 2 period, which included all patients randomized to treatment in the Phase 2 trial.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "meters", "timeFrame": "Baseline to 12 months", "groups": [{"id": "OG000", "title": "MYDICAR\u00ae Low Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6E11 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG001", "title": "MYDICAR\u00ae Mid Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3E12 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG002", "title": "MYDICAR\u00ae High Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1E13 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG003", "title": "Placebo", "description": "Single dose of placebo administered by antegrade epicardial coronary artery infusion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-167.9", "spread": "191.02"}, {"groupId": "OG001", "value": "-115.9", "spread": "226.56"}, {"groupId": "OG002", "value": "-23.7", "spread": "151.08"}, {"groupId": "OG003", "value": "-120.4", "spread": "181.41"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Phase 2: Change in Peak Maximum Oxygen Consumption (VO2) From Baseline to Month 12", "description": "Peak VO2 is a measure of maximal oxygen consumption during cardiopulmonary exercise testing; this study used the modified Naughton treadmill protocol. Higher values indicate a better functional status. Changes from baseline with negative values indicate a worsening in function and changes from baseline with positive values indicate an improvement in function.", "populationDescription": "This analysis was performed on the intention to treat population of the Phase 2 period, which included all patients randomized to treatment in the Phase 2 trial. Peak VO2 data were not available for one patient in the placebo group.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL/kg per minute", "timeFrame": "Baseline to 12 months", "groups": [{"id": "OG000", "title": "MYDICAR\u00ae Low Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6E11 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG001", "title": "MYDICAR\u00ae Mid Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3E12 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG002", "title": "MYDICAR\u00ae High Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1E13 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG003", "title": "Placebo", "description": "Single dose of placebo administered by antegrade epicardial coronary artery infusion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.00", "spread": "4.733"}, {"groupId": "OG001", "value": "-3.31", "spread": "5.473"}, {"groupId": "OG002", "value": "-1.57", "spread": "3.677"}, {"groupId": "OG003", "value": "-2.75", "spread": "5.084"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Phase 2: Change in Absolute Levels of N-terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) From Baseline to Month 12", "description": "NT-proBNP is a biomarker for heart failure. Increased levels of this biomarker are associated with increased mortality and cardiovascular hospitalization in patients with heart failure.", "populationDescription": "This analysis was performed on the intention to treat population of the Phase 2 period, which included all patients randomized to treatment in the Phase 2 trial. NT-proBNP data were not available for 1 patient in the MYDICAR high dose group.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL", "timeFrame": "Baseline to 12 months", "groups": [{"id": "OG000", "title": "MYDICAR\u00ae Low Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6E11 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG001", "title": "MYDICAR\u00ae Mid Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3E12 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG002", "title": "MYDICAR\u00ae High Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1E13 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG003", "title": "Placebo", "description": "Single dose of placebo administered by antegrade epicardial coronary artery infusion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3689.1", "spread": "5109.27"}, {"groupId": "OG001", "value": "8440.4", "spread": "11270.44"}, {"groupId": "OG002", "value": "1756.3", "spread": "4331.00"}, {"groupId": "OG003", "value": "11464.3", "spread": "16866.55"}]}]}]}, {"type": "POST_HOC", "title": "Phase 2: Selected Clinical Outcomes During 12-month Study Period", "description": "Incidences of key clinical endpoints as adjudicated by the blinded Clinical Endpoint Committee.", "populationDescription": "This analysis was performed on the intention to treat population of the Phase 2 period, which included all patients randomized to treatment in the Phase 2 trial.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "12 months", "groups": [{"id": "OG000", "title": "MYDICAR\u00ae Low Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6E11 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG001", "title": "MYDICAR\u00ae Mid Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3E12 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG002", "title": "MYDICAR\u00ae High Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1E13 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG003", "title": "Placebo", "description": "Single dose of placebo administered by antegrade epicardial coronary artery infusion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"title": "Fatal cardiovascular event", "categories": [{"measurements": [{"groupId": "OG000", "value": "12.5"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "7.1"}]}]}, {"title": "Worsening heart failure", "categories": [{"measurements": [{"groupId": "OG000", "value": "50.0"}, {"groupId": "OG001", "value": "37.5"}, {"groupId": "OG002", "value": "22.2"}, {"groupId": "OG003", "value": "50.0"}]}]}, {"title": "Myocardial infarction", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "14.3"}]}]}, {"title": "Heart failure-related hospitalization", "categories": [{"measurements": [{"groupId": "OG000", "value": "50.0"}, {"groupId": "OG001", "value": "37.5"}, {"groupId": "OG002", "value": "22.2"}, {"groupId": "OG003", "value": "42.9"}]}]}, {"title": "Silent myocardial infarction", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Receipt of left ventricular assist device", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "12.5"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "14.3"}]}]}, {"title": "Heart transplant", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "25.0"}, {"groupId": "OG002", "value": "11.1"}, {"groupId": "OG003", "value": "7.1"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Phase 2: Change in Percentage of Blood Ejected From the Left Ventricle (LV) (i.e., Left Ventricular Ejection Fraction [LVEF]) From Baseline to Month 12", "description": "Contrast echocardiography was used to determine LVEF. Increases in LVEF are associated with reduced mortality. Changes from baseline with positive values indicate an improvement in heart function and changes from baseline with negative values indicate a worsening of heart function.", "populationDescription": "This analysis was performed on the intention to treat population of the Phase 2 period, which included all patients randomized to treatment in the Phase 2 trial.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of blood ejected from the LV", "timeFrame": "Baseline to 12 months", "groups": [{"id": "OG000", "title": "MYDICAR\u00ae Low Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6E11 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG001", "title": "MYDICAR\u00ae Mid Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3E12 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG002", "title": "MYDICAR\u00ae High Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1E13 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG003", "title": "Placebo", "description": "Single dose of placebo administered by antegrade epicardial coronary artery infusion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-6.5", "spread": "7.26"}, {"groupId": "OG001", "value": "-5.6", "spread": "10.52"}, {"groupId": "OG002", "value": "0.3", "spread": "8.87"}, {"groupId": "OG003", "value": "-2.5", "spread": "9.96"}]}]}]}, {"type": "PRIMARY", "title": "Phase 2: Change in Percentage of Blood Ejected From the Left Ventricle (LV) (i.e., Left Ventricular Ejection Fraction [LVEF]) From Baseline to Month 6", "description": "Contrast echocardiography was used to determine LVEF. Increases in LVEF are associated with reduced mortality. Changes from baseline with positive values indicate an improvement in heart function and changes from baseline with negative values indicate a worsening of heart function.", "populationDescription": "This analysis was performed on the intention to treat population of the Phase 2 period, which included all patients randomized to treatment in the Phase 2 trial.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of blood ejected from the LV", "timeFrame": "Baseline to 6 months", "groups": [{"id": "OG000", "title": "MYDICAR\u00ae Low Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6E11 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG001", "title": "MYDICAR\u00ae Mid Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3E12 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG002", "title": "MYDICAR\u00ae High Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1E13 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG003", "title": "Placebo", "description": "Single dose of placebo administered by antegrade epicardial coronary artery infusion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "spread": "1.87"}, {"groupId": "OG001", "value": "-1.5", "spread": "6.35"}, {"groupId": "OG002", "value": "-0.7", "spread": "3.76"}, {"groupId": "OG003", "value": "-2.1", "spread": "6.90"}]}]}]}, {"type": "PRIMARY", "title": "Phase 2: Change in Absolute Left Ventricular End Systolic Volume (LVESV) Frm Baseline to Month 6", "description": "Contrast echocardiography was used to determine LVESV. Decreases in LVESV are associated with reduced mortality. Changes from baseline with positive values indicate a worsening in heart function and changes from baseline with negative values indicate an improvement in symptoms.", "populationDescription": "This analysis was performed on the intention to treat population of the Phase 2 period, which included all patients randomized to treatment in the Phase 2 trial.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL", "timeFrame": "Baseline to 6 months", "groups": [{"id": "OG000", "title": "MYDICAR\u00ae Low Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6E11 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG001", "title": "MYDICAR\u00ae Mid Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3E12 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG002", "title": "MYDICAR\u00ae High Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1E13 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG003", "title": "Placebo", "description": "Single dose of placebo administered by antegrade epicardial coronary artery infusion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.4", "spread": "26.16"}, {"groupId": "OG001", "value": "10.5", "spread": "45.91"}, {"groupId": "OG002", "value": "-9.6", "spread": "27.55"}, {"groupId": "OG003", "value": "18.2", "spread": "39.45"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Phase 2: Change in Absolute Left Ventricular End Systolic Volume (LVESV) From Baseline to Month 12", "description": "Contrast echocardiography was used to determine LVESV. Decreases in LVESV are associated with reduced mortality. Changes from baseline with positive values indicate a worsening in heart function and changes from baseline with negative values indicate an improvement in symptoms.", "populationDescription": "This analysis was performed on the intention to treat population of the Phase 2 period, which included all patients randomized to treatment in the Phase 2 trial.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL", "timeFrame": "Baseline to 12 months", "groups": [{"id": "OG000", "title": "MYDICAR\u00ae Low Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6E11 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG001", "title": "MYDICAR\u00ae Mid Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3E12 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG002", "title": "MYDICAR\u00ae High Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1E13 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG003", "title": "Placebo", "description": "Single dose of placebo administered by antegrade epicardial coronary artery infusion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "40.7", "spread": "59.79"}, {"groupId": "OG001", "value": "66.8", "spread": "103.12"}, {"groupId": "OG002", "value": "9.9", "spread": "49.27"}, {"groupId": "OG003", "value": "37.7", "spread": "69.09"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Phase 1 and Phase 2: All Subject Deaths Through 36 Months", "description": "All subject deaths that occurred during the 12-month study or the 24-month follow-up in subjects enrolled in either the Phase 1 or Phase 2 trial. Events occurring after early termination from the trial are listed as occurring during long-term follow-up, but may have been within 12 months. Specifically, two cardiovascular (CV) deaths in placebo subjects occurred following early study termination, but within 12 months of study initiation. These deaths are therefore included under \"Deaths within 12 months\" but also listed as \"Cardiovascular deaths in long-term follow-up.\" Accordingly, the number of \"Cardiovascular deaths in long-term follow-up\" for the placebo group is greater than the number of \"Deaths after 12 months,\" as 2 of the deaths occurred within 12 months but after early termination.", "populationDescription": "Includes all participants enrolled in the Phase 1 or Phase 2 trial. Events occurring after early termination are listed under long-term follow-up. The number of \"CV deaths in long-term follow-up\" for the placebo group is greater than the number of \"Deaths after 12 months,\" as 2 deaths occurred within 12 months but after early termination.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "36 months", "groups": [{"id": "OG000", "title": "MYDICAR\u00ae Very Low Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1.4E11 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG001", "title": "MYDICAR\u00ae Low Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6E11 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG002", "title": "MYDICAR\u00ae Mid Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3E12 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG003", "title": "MYDICAR\u00ae High Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1E13 DRP administered by antegrade epicardial coronary artery infusion."}, {"id": "OG004", "title": "All MYDICAR\u00ae", "description": "All participants who received a single infusion of MYDICAR\u00ae at any dose during the Phase 1 or Phase 2 studies."}, {"id": "OG005", "title": "Placebo", "description": "Single dose of placebo administered by antegrade epicardial coronary artery infusion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "11"}, {"groupId": "OG003", "value": "12"}, {"groupId": "OG004", "value": "37"}, {"groupId": "OG005", "value": "14"}]}], "classes": [{"title": "Deaths within 12 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "2"}, {"groupId": "OG005", "value": "3"}]}]}, {"title": "Deaths after 12 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "2"}, {"groupId": "OG004", "value": "8"}, {"groupId": "OG005", "value": "3"}]}]}, {"title": "Cardiovascular deaths on study", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "2"}, {"groupId": "OG005", "value": "1"}]}]}, {"title": "Cardiovascular deaths in long-term follow-up", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "2"}, {"groupId": "OG004", "value": "6"}, {"groupId": "OG005", "value": "4"}]}]}, {"title": "All deaths during 36 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "2"}, {"groupId": "OG004", "value": "10"}, {"groupId": "OG005", "value": "6"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "All treatment-emergent adverse events (TEAEs) that occurred from the time of first infusion of the investigational product or placebo through the 12-month visit.", "description": "These data include all TEAEs occurring during the Phase 1 or Phase 2 parts of this study.", "eventGroups": [{"id": "EG000", "title": "MYDICAR\u00ae Very Low Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1.4E11DRP administered by antegrade epicardial coronary artery infusion.", "seriousNumAffected": 2, "seriousNumAtRisk": 3, "otherNumAffected": 2, "otherNumAtRisk": 3}, {"id": "EG001", "title": "MYDICAR\u00ae Low Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6E11DRP administered by antegrade epicardial coronary artery infusion.", "seriousNumAffected": 6, "seriousNumAtRisk": 11, "otherNumAffected": 11, "otherNumAtRisk": 11}, {"id": "EG002", "title": "MYDICAR\u00ae Mid Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3E12 DRP administered by antegrade epicardial coronary artery infusion.", "seriousNumAffected": 5, "seriousNumAtRisk": 11, "otherNumAffected": 11, "otherNumAtRisk": 11}, {"id": "EG003", "title": "MYDICAR\u00ae High Dose", "description": "Single dose of MYDICAR\u00ae, a viral vector (adeno-associated virus serotype 1 \\[AAV1\\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1E13 DRP administered by antegrade epicardial coronary artery infusion.", "seriousNumAffected": 4, "seriousNumAtRisk": 12, "otherNumAffected": 11, "otherNumAtRisk": 12}, {"id": "EG004", "title": "Placebo", "description": "Single dose of placebo administered by antegrade epicardial coronary artery infusion.", "seriousNumAffected": 9, "seriousNumAtRisk": 14, "otherNumAffected": 13, "otherNumAtRisk": 14}], "seriousEvents": [{"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 3, "numAtRisk": 14}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 3, "numAtRisk": 14}]}, {"term": "Cardiac failure acute", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Arrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Cardiorenal syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 14}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Gastric ulcer haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Melaena", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Pancreatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Brain stem stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Pneumonia staphylococcal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Catheterization cardiac", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Heart transplant", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Vision blurred", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Colonoscopy", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Colon cancer metastatic", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Renal failure acute", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Rash maculo-papular", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA v 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Cardiogenic shock", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Sudden death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Orthopnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}], "otherEvents": [{"term": "Anemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 14}]}, {"term": "Arrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Cardiac aneurysm", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 3, "numAtRisk": 14}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Cardiogenic shock", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Extrasystoles", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Intracardiac thrombus", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Supraventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Ventricular fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Ventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 14}]}, {"term": "Hydrocele", "organSystem": "Congenital, familial and genetic disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "External ear disorder", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Hypothyroidism", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Vision blurred", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Abdominal distension", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Ascites", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 4, "numAtRisk": 14}]}, {"term": "Diarrhea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Epigastric discomfort", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Gastric ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 14}]}, {"term": "Catheter site hematoma", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Catheter site hemorrhage", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Chills", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 4, "numAtRisk": 14}]}, {"term": "Feeling jittery", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Gait disturbance", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Influenza like illness", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Infusion site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Edema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Edema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Puncture site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 14}]}, {"term": "Venipuncture site thrombosis", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Jaundice", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 14}]}, {"term": "Candidiasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Central line infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Gastric ulcer Helicobacter", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Herpes zoster", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 14}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 14}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Excoriation", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 14}]}, {"term": "Eye injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Head injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Mouth injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Post procedural discharge", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Tendon injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Blood bilirubin increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Blood creatinine phosphokinase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Blood creatinine phosphokinase MB increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Blood magnesium decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Blood triglycerides increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Blood uric acid increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Carcinoembryonic antigen increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Gallop rhythm present", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 14}]}, {"term": "Hepatic enzyme increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "International normalized ratio increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Liver function test abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Mean cell volume increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Muscle enzyme increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Prostatic specific antigen increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Transaminases increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Troponin increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Vitamin D decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Weight increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Anorexia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Decreased appetite", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Fluid overload", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Fluid retention", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Gout", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 4, "numAtRisk": 14}]}, {"term": "Hyperkalemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 14}]}, {"term": "Hyperlipidemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Hyperuricemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Hypervolemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Hypokalemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Hyponatremia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Hypovolemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Type 2 diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 14}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Bone disorder", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Bursitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Groin pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Muscle spasms", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Muscle tightness", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Muscular weakness", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Musculoskeletal chest pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Musculoskeletal discomfort", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Asterixis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 4, "numAtRisk": 14}]}, {"term": "Dizziness postural", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 14}]}, {"term": "Hepatic encephalopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Hypoesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Neurological symptom", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Nystagmus", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Paresthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Restless leg syndrome", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Somnolence", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Alcoholism", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 14}]}, {"term": "Bruxism", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 3, "numAtRisk": 14}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Mental status changes", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Somnambulism", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Azotemia", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 14}]}, {"term": "Hematuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Renal failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Renal failure acute", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Renal impairment", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Breast disorder", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Gynecomastia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Variocele", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 14}]}, {"term": "Dyspnea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Dyspnea exertional", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Hemoptysis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Nasal congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Oropharyngeal discomfort", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Orthopnea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Productive cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Pulmonary hypertension", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Rales", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Sleep apnea syndrome", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Wheezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Cold sweat", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Ecchymosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Hemorrhage subcutaneous", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Rash generalized", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Skin ulcer", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Stevens-Johnson syndrome", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Cataract operation", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Hematoma", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 14}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 12}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 14}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Limitations of this study include its small sample size and the inability to conclusively prove that the delivered gene was responsible for the observed clinical effects. Larger confirmatory trials are needed."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Jeffrey J. Rudy, Vice President", "organization": "Celladon Corporation", "email": "jrudy@celladon.net", "phone": "1 858-366-4288"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}, {"id": "D000009202", "term": "Cardiomyopathies"}, {"id": "D000002311", "term": "Cardiomyopathy, Dilated"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000006332", "term": "Cardiomegaly"}, {"id": "D000083083", "term": "Laminopathies"}, {"id": "D000030342", "term": "Genetic Diseases, Inborn"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M12154", "name": "Cardiomyopathies", "asFound": "Cardiomyopathy", "relevance": "HIGH"}, {"id": "M5567", "name": "Cardiomyopathy, Dilated", "asFound": "Dilated Cardiomyopathy", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M9420", "name": "Cardiomegaly", "relevance": "LOW"}, {"id": "M2392", "name": "Laminopathies", "relevance": "LOW"}, {"id": "M23686", "name": "Genetic Diseases, Inborn", "relevance": "LOW"}, {"id": "T1876", "name": "Dilated Cardiomyopathy", "asFound": "Dilated Cardiomyopathy", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC16", "name": "Diseases and Abnormalities at or Before Birth"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M3595", "name": "Adenosine", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "Analg", "name": "Analgesics"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}